{"schema_version":"secwatch.filing_event.v1","accession":"0002019410-26-000019","form_type":"8-K","ticker":"CAI","cik":"0002019410","company_name":"Caris Life Sciences, Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.389002+00:00","generated_at":"2026-05-15T07:53:27.175975+00:00","sec_items":["1.01","1.02","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Caris Life Sciences enters $400M term loan and $300M delayed draw facility with Blue Owl and Blackstone","bullets":["Borrowed $400M initial term loan to repay existing credit agreement from January 2023.","Additional $300M delayed draw facility for acquisitions available through August 2027.","Uncommitted incremental capacity up to $500M; loans priced at SOFR + 5.00%.","Credit agreement matures April 2031; secured by substantially all assets.","Must maintain minimum $50M qualified cash tested quarterly."],"urls":{"canonical":"https://secwatch.observer/filing/0002019410-26-000019","json":"https://secwatch.observer/filing/0002019410-26-000019.json","markdown":"https://secwatch.observer/filing/0002019410-26-000019.md","text":"https://secwatch.observer/filing/0002019410-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:53:27.175975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f4acc9b8602a48859e8ac04773926e22112e7e7","claim":"Caris Life Sciences, Inc. incurred credit facility of $400,000,000 initial term loan, up to $300,000,000 delayed draw facility, and up to $500,000,000 uncommitted incremental with Blue Owl Capital and Blackstone at Term SOFR Rate or Base Rate plus 5.00% or 4.00%, respectively maturing Initial Term Facility matures in April 2031; Delayed Draw Facility available through August 2027.","evidence_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","confidence":0.95},{"claim_id":"966236c1aafd829ee691b98169036019c38ff122","claim":"Caris Life Sciences, Inc. entered into New Credit Agreement with Blue Owl Capital and Blackstone valued at Senior secured credit facilities: $400M initial term loan, $300M delayed draw, $500M incremental fac (effective 2026-04-01).","evidence_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","confidence":0.9},{"claim_id":"b6e34681e3b08597ea60b0af74694e236d6571a8","claim":"Caris Life Sciences, Inc. terminated Previous Credit Agreement with Wilmington Trust, National Association valued at Repaid all outstanding indebtedness and terminated guarantees, liens, and security interests under t (effective 2026-04-01).","evidence_excerpt":"On the Closing Date, the Company used proceeds under the Initial Term Facility to repay all outstanding indebtedness under that certain credit agreement, dated as of January 18, 2023, by and among the Company, certain of the Company’s subsidiaries, the lenders from time to time party thereto and Wilmington Trust, National Association, as administrative agent, as amended (the “ Previous Credit Agreement ”). The Company terminated all guarantees, liens and other security interests granted under and terminated the Previous Credit Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001140361-26-023577","ticker":"TCPC","company_name":"BlackRock TCP Capital Corp.","filed_at":"2026-06-01T20:50:02+00:00","headline":"BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities","event_type":"debt","sec_items":["1.01","1.02","2.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 1.02, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023577","json":"https://secwatch.observer/filing/0001140361-26-023577.json","markdown":"https://secwatch.observer/filing/0001140361-26-023577.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/ef20075169_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","comparable_excerpt":"Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the \" Closing Date \"), BlackRock TCP Capital Corp. (the \" Company \"), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the \" CLO Transaction \"). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm"}},{"accession":"0001606268-26-000029","ticker":"VIASP","company_name":"Via Renewables, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Via Renewables enters $300M senior secured revolving credit facility, replaces prior agreement","event_type":"debt","sec_items":["1.01","1.02","2.03","3.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 1.02, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001606268-26-000029","json":"https://secwatch.observer/filing/0001606268-26-000029.json","markdown":"https://secwatch.observer/filing/0001606268-26-000029.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000029/0001606268-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000029/spke-20260506.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","comparable_excerpt":"In connection with entering into the Credit Agreement, the Company entered into an amended and restated subordinated promissory note (Note No. 9) (the “Subordinated Debt Facility”) with Spark HoldCo and Retailco, LLC (“Retailco”). The Subordinated Debt Facility allows the Company to draw advances in increments of no less than $1.0 million per advance up to $25.0 million through November 6, 2029.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1606268/000160626826000029/0001606268-26-000029-index.htm"}},{"accession":"0000785161-26-000161","ticker":"EHC","company_name":"Encompass Health Corp","filed_at":"2026-06-01T20:26:16+00:00","headline":"Encompass Health issues $500M 5.875% notes due 2034; to redeem $400M of 4.500% notes due 2028","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000785161-26-000161","json":"https://secwatch.observer/filing/0000785161-26-000161.json","markdown":"https://secwatch.observer/filing/0000785161-26-000161.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/0000785161-26-000161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/ehc-20260529.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","comparable_excerpt":"On May 29, 2026, Encompass Health Corporation (the “Company”) completed the issuance and sale of $500 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the “Notes”), along with the related guarantees of the Notes by certain of the Company’s subsidiaries (the “Guarantees”), in a private offering.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/0000785161-26-000161-index.htm"}},{"accession":"0001193125-26-214205","ticker":"PGIM","company_name":"PGIM Private Credit Fund","filed_at":"2026-05-08T23:59:59+00:00","headline":"PGIM Private Credit Fund enters $100M credit facility with $500M accordion option","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214205","json":"https://secwatch.observer/filing/0001193125-26-214205.json","markdown":"https://secwatch.observer/filing/0001193125-26-214205.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1923622/000119312526214205/0001193125-26-214205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1923622/000119312526214205/ck0001923622-20260505.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","comparable_excerpt":"Repo Rate Average; and for Australian‐dollar advances, Bank Bill Swap Rate), in each case subject to a 0.25% floor. The initial facility amount of the Credit Facility is $100 million, with an accordion feature that permits increases, with the consent of the facility agent and the lenders, up to an aggregate commitment of $500 million. The Credit Facility has","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1923622/000119312526214205/0001193125-26-214205-index.htm"}},{"accession":"0001335258-26-000023","ticker":"LYV","company_name":"Live Nation Entertainment, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Live Nation VenueCo closes €610M secured notes issuance backed by 4 venues","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001335258-26-000023","json":"https://secwatch.observer/filing/0001335258-26-000023.json","markdown":"https://secwatch.observer/filing/0001335258-26-000023.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335258/000133525826000023/0001335258-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335258/000133525826000023/lyv-20260508.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","comparable_excerpt":"On May 8, 2026, Live Nation VenueCo, LLC (“VenueCo”), a bankruptcy-remote, special purpose vehicle owned by certain bankruptcy-remote, special purpose entities (the “Participants”), which are indirect subsidiaries of Live Nation Entertainment, Inc. (the “Company”), closed its previously announced issuance of €610 million aggregate principal amount of fixed rate senior secured notes (the “Notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335258/000133525826000023/0001335258-26-000023-index.htm"}},{"accession":"0001342916-26-000028","ticker":"HNOI","company_name":"HNO International, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"HNO International issues $67,500 convertible note and warrant to Monroe Street Capital","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001342916-26-000028","json":"https://secwatch.observer/filing/0001342916-26-000028.json","markdown":"https://secwatch.observer/filing/0001342916-26-000028.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1342916/000134291626000028/0001342916-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1342916/000134291626000028/hnoi8k5526.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","comparable_excerpt":"On May 5, 2026, HNO International, Inc. (the \"Company\") entered into a Securities Purchase Agreement (the \"MSC Purchase Agreement\") with Monroe Street Capital Partners, LP, a Delaware limited partnership (the \"MSC Buyer\"), pursuant to which the Company issued to the MSC Buyer a Convertible Promissory Note in the principal amount of $67,500","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1342916/000134291626000028/0001342916-26-000028-index.htm"}},{"accession":"0000053456-26-000012","ticker":null,"company_name":"JERSEY CENTRAL POWER & LIGHT CO","filed_at":"2026-05-07T23:59:59+00:00","headline":"JCP&L issues $350M of 4.600% Senior Notes due 2030 for refinancing and capex","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000053456-26-000012","json":"https://secwatch.observer/filing/0000053456-26-000012.json","markdown":"https://secwatch.observer/filing/0000053456-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/53456/000005345626000012/0000053456-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/53456/000005345626000012/jcpl-20260504.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","comparable_excerpt":"On May 6, 2026 (the “Closing Date”), Jersey Central Power & Light Company (the “Company”) completed its offering of $350,000,000 aggregate principal amount of its 4.600% Senior Notes due 2030 (the “Notes”)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/53456/000005345626000012/0000053456-26-000012-index.htm"}},{"accession":"0001104659-26-057239","ticker":"BKNG","company_name":"Booking Holdings Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Booking Holdings issues $750M of 5.375% Senior Notes due 2036","event_type":"debt","sec_items":["1.01","2.03","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057239","json":"https://secwatch.observer/filing/0001104659-26-057239.json","markdown":"https://secwatch.observer/filing/0001104659-26-057239.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1075531/000110465926057239/0001104659-26-057239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1075531/000110465926057239/tm2613920d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm","comparable_excerpt":"in connection with the sale of $750,000,000 aggregate principal amount of the Company’s 5.375% Senior Notes due 2036","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1075531/000110465926057239/0001104659-26-057239-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}